Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for Evorpacept (ALX148) + Zanidatamab in Breast cancer, Cancer. The expected timing is based on the latest available company guidance and may change.
Dosed first patient in October 2021. Evorpacept selected for Ph1 combo trial w/ ENHERTU. In December 2022, Zymework licensed zanidatamab to Jazz & Jazz will be responsible for managing future zanidatamab-related clinical trials. 11/1/24 New Ph1/2 data at SABCS '24. 12/10/24- Ph1b/2 data show encouraging clinical activity, well tolerated with a manageable safety profile. 11/07/25:- PR No update. 01/30/26:- Exploratory Ph1b/2 analysis links higher CD47 to response; full biomarker dataset submitted to upcoming scientific congress. 02/27/26:- Full Ph1b/2 biomarker analysis accepted for ESMO Breast Cancer 2026 poster on May 7, 2026. 05/07/26:- ESMO Breast Cancer 2026 NCT05027139: CD47-high centrally confirmed HER2+ metastatic breast cancer showed 100% confirmed objective response rate. 05/08/26:- ESMO Breast 2026 Ph1b/2 zanidatamab trial: ccHER2+ 60% cORR, CD47-high 100% responses with prolonged PFS. 08/06/26:- ESMO Breast 2026 data reiterated durable responses in ccHER2-positive, CD47-high metastatic breast cancer.
Verification
Confirm timing and program details against the company announcement or filing.